Hisam Siddiqi: Understanding Bone Marrow Trephine Morphology in MPNs
Hisam Siddiqi, Consultant Haematologist at LycaHealth, The Blackheath Hospital, Dartford and Gravesham NHS Trust, shared a post on LinkedIn:
“Understanding Bone Marrow Trephine Morphology in MPNs – A Simple Breakdown
Myeloproliferative neoplasms (MPNs) can often look similar clinically, but the bone marrow trephine provides important clues that help us distinguish between them.
Here’s a quick, simplified guide to typical findings across the main MPN subtypes, based on key features: cellularity, megakaryocyte morphology, clustering patterns, and reticulin fibrosis.
Polycythaemia Vera (PRV)
- Cellularity: Very high (panmyelosis – all cell lines increased)
- Megakaryocytes: Mildly increased
- Clusters: Usually absent
- Reticulin: Normal or slightly up
- Think: a busy marrow with everything ‘turned up.’
Essential Thrombocythaemia (ET)
- Cellularity: Normal
- Megakaryocytes: Markedly increased, hyperlobulated (‘staghorn’)
- Clusters: None or loose
- Reticulin: Normal or slightly up
- Think: lots of large, mature megakaryocytes with big, multilobed nuclei.
Pre‑Fibrotic Myelofibrosis (pre‑MF)
- Cellularity: Increased
- Megakaryocytes: Variable up; abnormally shaped, atypical, hypolobulated
- Clusters: Small, dense or loose
- Reticulin: Mildly up
- Think: dysplastic megakaryocytes plus early scarring.
Overt Myelofibrosis (MF)
- Cellularity: Often reduced
- Megakaryocytes: Increased, hypolobulated / atypical
- Clusters: Dense, tight clusters
- Reticulin: Marked fibrosis with collagen deposition
- Think: fibrotic, scarred marrow with abnormal megakaryocyte clusters.
Why this matters:
Trephine morphology remains central to accurate MPN diagnosis and helps guide prognosis and treatment decisions. Recognising these hallmark patterns can refine our diagnostic confidence and improve patient care.”
More posts featuring Hisam Siddiqi on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS